Cartherics Pty Ltd

The future of cancer treatment, off-the-shelf cellular immunotherapy for cancer. At Cartherics we are developing the next generation of improved and optimized chimeric antigen receptor CAR-T cell products. We use three unique proprietary approaches to produce individual CAR-T products that can be used by a large number of cancer patients. These three novel technologies set Cartherics apart from other CAR-T companies: 1. Development of CAR-T cells expressing two or more receptors specific for cancer stem cells to avoid the cancer escaping recognition, and also to enhance the attachment and killing by the CAR-T cells. 2. Allogeneic stem cells that can be used for compatible transplants for cancer therapy. 3. Production of a limitless supply of cancer killing CAR-T cells, using proprietary differentiation to create fully functional T cells engineered to contain the selected CAR and T cell receptor (TCR) genes. Transforming cancer from a fatal disease to a manageable condition.